Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $147.50

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned an average recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $147.50.

PCVX has been the subject of a number of research analyst reports. BTIG Research upped their target price on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC raised their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Leerink Partners upped their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Mizuho raised their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Finally, Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th.

Vaxcyte Trading Up 0.6 %

PCVX stock opened at $112.94 on Wednesday. The stock has a market cap of $12.29 billion, a P/E ratio of -26.39 and a beta of 0.99. Vaxcyte has a twelve month low of $45.61 and a twelve month high of $121.06. The company’s 50 day moving average is $106.09 and its two-hundred day moving average is $84.46.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) EPS. On average, equities research analysts predict that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 42,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,429,294.37. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Andrew Guggenhime sold 42,000 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,429,294.37. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $37,822,574.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,098 shares of company stock valued at $9,937,773 in the last ninety days. 3.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Vaxcyte by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after buying an additional 168,125 shares during the period. PNC Financial Services Group Inc. grew its holdings in Vaxcyte by 25.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock valued at $439,000 after purchasing an additional 1,411 shares during the period. Banque Cantonale Vaudoise grew its holdings in Vaxcyte by 96.7% in the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock valued at $81,000 after purchasing an additional 582 shares during the period. Allspring Global Investments Holdings LLC increased its position in Vaxcyte by 109.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company’s stock worth $3,237,000 after purchasing an additional 24,785 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Vaxcyte by 11.8% during the first quarter. Principal Financial Group Inc. now owns 24,597 shares of the company’s stock worth $1,680,000 after purchasing an additional 2,589 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.